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Background: In an attempt to engineer a regulatory compliant form of cell assisted lipotransfer in the U.S., the authors
developed Autologous Fat Transfer with In-situ Mediation (AIM) for reconstruction of a refractory surgical scar.
Methods: This method incorporates use of accepted standard procedures like autologous fat grafting and
intradermal injection of NB6 collagenase to release adipose stem cells from a naturally occurring high concentration
stromal vascular fraction (SVF) fat graft. To prevent off-target effects of collagenase, a hyaluronic acid and serum
deactivation barrier is placed circumferentially around the operative site.
Findings: This novel protocol was well tolerated by the patient and improved scar appearance, mobility and
texture. Deepest scar contour defect correction was 80% and 77% at 4 and 12 weeks respectively.
Conclusion: AIM appears to be a practical and viable option for scar reconstruction requiring small to moderate
volume correction.Background
Cell assisted lipotransfer (CAL), a process whereby free fat
grafting is enriched with a supraphysiologic level of
autologous stromal vascular fraction (SVF) cells (which
include autologous adipose stem cells), has been utilized
for nearly a decade in Japan for tissue augmentation and
reconstruction [1]. Thus far CAL, under appropriate con-
ditions, appears to be clinically efficacious and safe [2].
Within the United States, practitioners are confronted
with regulatory issues of 21 CFR 1271 and concerns that a
lengthy Investigational New Drug (IND) process is neces-
sary for CAL use to be legal according to formal Requests
for Determination now disclosed in the public domain.
Further questions remain as to whether or not a key step
in CAL (ex-vivo enzymatic separation of SVF and concen-
tration by centrifugation) constitutes a greater than “min-
imal manipulation” procedure despite being done in the
same surgical setting. The defining lower limits of what
constitutes “minimal manipulation” have not been fully
articulated directly by the Food and Drug Administration* Correspondence: gedanken7@yahoo.com
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distribution, and reproduction in any medium(FDA) at this juncture, and for this important reason
plastic, cosmetic and reconstructive surgeons within
the States struggle to find a practical and clearly com-
pliant means of providing some form of CAL or adult
mesenchymal stem cell therapy. Meanwhile the ever
marching reality of refractory wounds, scar revisions,
congenital abnormalities which have exhausted standard
medical therapy continue to grow and remain untreated.
Historically, the procedures of: 1. autologous fat
transplant (AFT), 2. in-vivo high quality current good
manufacturing practice (cGMP) grade collagenase in-
jection, 3. dermal chemical peeling and 4. dermal
hyaluronic acid (HA) fillers are widely considered
acceptable, safe and routine standards of medical care
in the United States and abroad. We postulated on the
outset of this case study that fat retaining pre-existing
high concentrations of SVF/ADSC could be transferred
under routine AFT methods, but further treated with
collagenase subcutaneously to release or migrate ADSC
off the collagen matrix into a wound bed or chemically
peeled skin. A “ring” or moat of HA admixed with
autologous serum surrounding the collagenase couldtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Images of standard lipoaspirate (top container) after
Coleman technique separated into aqueous phase (far left
container) and yellow appearing low SVF fat (center container)
and orange appearing high SVF (right container). (Oil phase not
pictured.) Because the fat is already pre-washed, the heme
pigmentation is not a result of contaminated red blood cells (RBCs),
but rather RBCs that are still within the perivascular space thereby
creating an indirect marker for a fat fraction rich in perivascular cells
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http://www.translational-medicine.com/content/11/1/136also be placed as a deactivation barrier to prevent off-
target or off-site effects of collagenase. This “under the
skin” mediated approach using accepted standard of
care techniques and materials avoids contentious ex-
vivo manipulation, thereby allowing practitioners a
potentially regulatory compliant form of regenerative
surgery for soft tissue reconstruction. We have com-
bined the stated standard of care procedures in a
unique sequence to treat a patient that failed standard
fat transfer for correction of a contracted and excavated
scar sustained after previous lipoma excision.
Methods
Patient was selected for having failed previous standard
AFT 2 years previously for correction of an adherent
cicatrix scar sustained on the right lower back after
lipoma excision. The procedure was performed in a
fully accredited ambulatory surgery center staffed by a
physician anesthesiologist. A comprehensive and tho-
rough pre-operative consultation and specific consent
for percutaneous aponeurotic lipofilling (PALF) with
AFT in conjunction with collagenase and HA-serum
was obtained.
Autologous fat was harvested from the anterior ab-
dominal wall using standard Klein tumescent solution
and a 2 mm inner diameter cannula (Mentor BENSAT
330). Negative pressure was limited to 350 mmHg.
Lipoaspirate was washed three times with normal saline
and gravitational decanting was used to remove as much
aqueous phase possible. Fat was then centrifuged and
purified under standard Coleman technique (i.e. cen-
trifugation at 1,000 RCF for 3 minutes followed by
immediate decantation of oil and aqueous phase) [3,4].
Lipoaspirate was further processed to separate SVF rich
fat (Figure 1) using a non-invasive proprietary method of
spectroscopy (Patent publication number EP2346989
A1). PALF was performed on the subdermal bed of the
scar directly adherent to the erectus spinae muscle
(Figure 2A) [5]. AFT was performed by the minimal
barotrauma method of reverse injection at 3-5 cc per
pass layering thin ribbons of graft using a blunt
spatulated tip (Marina Medical 20–1415) through 6 stra-
tegically placed 5 mm adits at 20% overcorrection at the
deepest excavation point using 100 cc total (Figure 2B).
A 2 cm wide ring of SVF rich fat (60 cc) was distributed
circumferentially around the wound bed. A perimeter of
and underlying layer of HA-serum filler (0.5 cc auto-
logous serum to 1 cc of HA filler) was placed in a cross-
hatched fashion using a 22 gauge spinal needle
(Figures 2C, 3, and 4).
Collagenase was prepared by serially diluting NB6 col-
lagenase (GMP grade 17458 SERVA Electrophoresis,
Nordmark GmBH, Crescent Chemical) with PBS (GMP
grade D8662 Sigma) to a final concentration of 0.1 PZ-U/mL (Figures 2D and 3). A total of 10 cc of dilute NB6
was distributed with a 25 gauge needle within the dermis
holding SVF rich graft. Wet application of T10 chemical
peel, without deep scrubbing, was placed over the skin
directly overlying the PALF wound bed, but not directly
above the scar itself. After the skin was left to air dry a
non-adherent (100540/960482, Kendall, Tyco Healthcare)
occlusive dressing (1626, 3 M Corporation) was applied.
Patient was placed on activity restriction to prevent
direct compression of the nascent graft and received
3 days of post operative IV antibiotics (Cefotetan 2 gm
q24 hours) followed by 7 days of oral antibiotics (Keflex
500 mg BID).
Post operative photography and ultrasounds (Acuson
7 mHz flat probe) were obtained days 1–5 and 1, 2, 4, 8
and 12 weeks following surgery.
Results
PALF and AFT were able to immediately resolve adher-
ence of the scar directly against the muscle without
Figure 2 Images of procedures utilized for AIM technique. PALF maneuvers (A) are done prior to autologous fat grafting (B). A concentric
ring and undermined cross-hatching with an HA-serum barrier (C) is placed prior to collagenase NB6 injection (D). (Note the natural amber
appearance of collagenase). Overlying skin, but not scar, is then chemically treated with 10% TCA in a single “wet” coat without deep scrubbing
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pation post-operative days 1 through 5 and weeks 2
through 4 did not reveal any subcutaneous fremitus or
hypermobility of scar.
Unlike typical AFT, the wound bed did not exhibit
the typical induration swelling phase, and echymossis
formation was minimal. An unexpected finding at
12 hours post procedure was the complete epithelializa-
tion of the six operative incisions (5 mm) over the
wound bed. In comparison, the 5 mm incisions over
the abdomen used for liposuction were not even par-
tially epithelialized despite absence of drainage and
placement of 3–0 Nylon sutures immediately following
liposuction. Desquamation of overlying skin was not
appreciated with the chemical peel. Qualitatively the
lateral most aspects of the scar exhibited signs of re-
modeling based on softening texture, fibrotic scarheight and color blending with surrounding normal
skin (Figures 5, 6 and 7). Pre-operative pain associated
with extreme flexion of the right erectus spinae muscle
resolved at 6 weeks.
Ultrasound revealed correction of 77% of the original
excavated defect at the maximal depth. The lateral
aspect of the scar showed 100% correction at 3 months
out from the original procedure (Figure 5).Discussion
The authors emphasize that based on current literature
CAL appears to be a safe and efficacious procedure
[6-8]. Although CAL may be performed under an IRB or
IND based clinical study in the U.S., the reality of not
being able to perform procedures unapproved by the
FDA, either from a liability insurance or institutional
Figure 3 Photograph of all FDA approved and cGMP
materials used for the AIM technique. Standard HA without
lidocaine and cGMP NB6 collagenase are critical starting
reagents. The blunt cannula (far left) may be substituted with a
spinal needle to allow longer tracts for barrier formation. A
yellow top vacutainer may also be used with 1 cc of dilute
Heparin instead of a conical centrifuge tube. Red Luer lock
connectors (center bottom) can be obtained in premade dermal
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practitioner from providing the service. Trichloroacetic
acid (TCA) chemical peeling of the skin has been widely
used through out dermatology and plastic aesthetic
surgery for skin resurfacing and remodeling [9,10]. Col-
lagenase has been utilized in-vivo extensively in recon-
structive surgery to facilitate anesthesia and dissection of
skin flaps, fibrotic tissue and correction of misplaced
dermal fillers [11-13]. It has also been commonly used
as a debriding topical agent for wound care [14]. FDA
approved hyaluronic acid based dermal fillers have also
been safely employed for reconstructive reasons [15-17].Figure 4 Mixture of platelet poor serum and HA dermal filler
using Luer lock connector and back-and-forth mixing with
syringe pistons. Note: the meniscus of serum and HA is brought to
the highest level of the Luer lock or connector hub prior to mixing
to minimize presence of air bubbles.However, of all the procedures mentioned, autologous
fat grafting has the longest track record of use well prior
to the advent of modern medicine [18]. These safe and
FDA allowable procedures when combined using the
protocol presented, should provide some practitioners a
means of practicing a form of regenerative surgery with-
out legal regulatory repercussion. However, the use of an
FDA approved material for a new indication is con-
sidered “off-label” use, and while not illegal, it is not
without clinical risk if sound medical judgment is igno-
red. The authors also emphasize the important
distinction that although the independent incremental
procedures used are standard of care, many accepted
standard surgical procedures performed in the United
States are never granted “approval” by the FDA, as the
jurisdiction of purely surgical procedures is in large
part the domain of State medical boards and profes-
sional organizations. (The authors in no way state or
imply that the AIM procedure is endorsed or approved
by the FDA.)
Unique to this procedure is the isolation of native high
SVF fat. This can be achieved by visual inspection and
volumetric location alone [19]. However, with small
volume fat extraction, use of non-invasive spectroscopy
to measure surrogate markers of pericyte loci provides
maximum harvest of this essential graft, which visual
inspection can under calculate [20]. It is also important
to emphasize that well characterized high grade cGMP
collagenase near absent of endotoxin is critical for direct
in-vivo use and may be prove critical for creating a
directional migration of ADSC when employing this
technique. Our choice of NB6 was prompted by his-
torical data and full disclosure readily provided by the
manufacturer regarding cGMP and endotoxin status
(<< 11 I.U./mg). Custom compounded collagenase com-
mercially available within the United States does not
always carry as copious of manufacturing documenta-
tion, and with recent concerns of sterility and safety of
compounded preparations, use of high quality cGMP
material is strongly recommended for this unique appli-
cation [21].
Due to previous keloid formation on her back, the
patient refused to consent for biopsy of the wound area
post operatively. This clinical dilemma has lead to a
confusion of sorts with respect to precisely elucidating
the exact mechanism of action for this procedure and
why it was successful versus standard AFT. Mechanical
dissociation and graft migration as the key mechanism is
unlikely, as one would expect the majority of volume
augmentation to settle towards the dependent areas of
the back, which is not supported by photographic and
ultrasound data. TCA causing direct scar remodeling is
also another possible mechanism, but is highly unlikely
given the strength of TCA used in this study is over a
Figure 5 Before (left panel) and after (right panel) photographic images and corresponding ultrasounds (green arrows) documenting
correction of contour defect seen at 12 weeks post procedure. Ultrasound images were obtained using a 7 mHz probe and placed
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Figure 6 Before (left panel) and after (right panel) photographs of scar during full flexion of back accentuating medial
excavation or “atrophy” of subcutaneous fat and upper dermis tissue (left panel). Post operative image of same scar following AIM
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deling studies [10]. Furthermore, TCA was not applied
directly to the scar itself and desquamation, a common
sign of deep dermal peeling, was never observed in this
case. Remaining possible mechanisms include direct
factor signaling [22] of detached SVF/ADSC versus
migration of ADSC into the wound site from the
surrounding SVF rich graft. Collagenase in this context
could not only form the basis for ADSC release, but also
provide microscopic conduits similar to the PALF
procedure, wherein migrating cells gain direct physical
pathways to areas requiring regeneration (Figures 8 and 9)
[23]. Of the two remaining theories the concept of stem cell
in-vivo migration has been suggested previously, but only
from the perspective of mobilizing marrow mesenchymal
stem cells [24]. The concept of in-vivo migration in our
model system implies a lesser distance to travel andFigure 7 Before (left panel) and after (right panel) photographs of sca
softening and remodeling of scar and overlying skin at 12 weeks pos
adherence of scar with muscle flexion. Note that both erectus spinae m
dissipated and metabolized at 12 weeks and ultrasound was still able to co
(not pictured).perhaps a greater local effect, since adipose tissue inherently
retains one of the highest concentrations of mesenchymal
stem cells for any tissue in the human body [25]. We
propose AFT with in-situ mediation (AIM) of ADSC via
light concentration collagenase in-vivo is a tenable form of
regenerative therapy with minimal side-effect to the patient.
Although it was not the intent of this pilot study to
elucidate the theoretical underpinnings for why the novel
procedure works, further confirmatory studies using
animal models will need to be performed. (However, curs-
ory results of nude-mice studies, simultaneously being
pursued by our group appear promising.) The authors
fully acknowledge this is a single case study with remark-
able results the reproducibility of which will need to be
verified with further study. In light of this, three other
patients have been treated using the same protocol in
other regions of the body with no adverse or safety events.r during full flexion of right erectus spinae muscle showing
t procedure (right panel) in addition to less movement and
uscles of the back were fully functional as local lidocaine was fully
nfirm the underlying voluntary movement and flexion of muscles
Figure 8 Conceptual cross-sectional drawing of different therapeutic layers and their relationship to the scar (in red), dermis (dotted blue
line) and grafts (yellow ovoid and orange crescent). The upper fat graft (yellow ovoid) serves and the primary reconstructive and augmenting
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http://www.translational-medicine.com/content/11/1/136At this juncture, precaution is advised in extrapolating this
procedure to large volume augmentations used in full
breast or buttock augmentation. Use of the procedure on
smaller lesions such as chronic lower extremity wounds,
which allow adequate circumscribing with an HA-serum
deactivation zone, is ideal and will be the focus of pending
clinical investigations at our institution.Figure 9 Conceptual and theoretical cross-sectional drawing of AIM p
(shaded crescent). Adipose mesenchymal stem cells are then freed from
or become activated to secrete paracrine mediators of wound healing and
peel (green line) is NOT placed directly over the scar itself.Conclusion
In-vivo use of NB6 collagenase subdermally is well
tolerated and well suited for the AIM technique.
The AIM procedure itself also appears safe and capable
of providing contour correction and soft-tissue re-
construction and augmentation where standard AFT
might fail.rocedure after high SVF fat graft matrix is digested in-vivo
the native fat matrix to potentially migrate in direction of wound bed
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